AI brief of an SEC Form 8-K · ORAGENICS INC (OGEN)

Oragenics receives NYSE American equity deficiency notice; shares tagged .BC

Negative Impact 4 of 5 legal/regulatory Written later

Oragenics said NYSE American notified it on August 26, 2026 that it is below the continued listing standards for stockholders' equity. The company reported stockholders' equity of $3.7 million at June 30, 2026, and the exchange requires $6 million because the company had net losses in its five most recent fiscal years. The notice does not immediately affect the listing, but if the company does not meet the requirements, it could face delisting, which the filing says could reduce the stock's liquidity and market price.

Key points

  • Stockholders' equity was $3.7 million at June 30, 2026; the NYSE American standard cited requires $6 million.
  • A compliance plan is due to NYSE American by September 25, 2026, and the company must regain compliance by February 25, 2028.
  • Shares continue to trade as OGEN with a ".BC" (below compliance) designation during the plan period.
  • The company says it will endeavor to undertake a transaction in the future to achieve compliance, but gives no assurance it will succeed.

The filing

CompanyORAGENICS INC (OGEN)
Form8-K, current report
Filed with the SECAug 28, 2026, 5:06 PM ET
Accession number0001493152-26-040645

Items reported: 3.01 Delisting / Listing Rule Notice8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.